Immunotherapy with a HER2 targeted Listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma.

CONCLUSIONS: These findings demonstrate that ADXS31-164 administered in the setting of minimal residual disease, can induce HER2/neu specific immunity and may reduce the incidence of metastatic disease and prolong overall survival in a clinically relevant, spontaneous, large animal model of cancer. These findings therefore, have important translational relevance for children with osteosarcoma and adults with other HER2/neu+ cancers. PMID: 26994144 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research